MDA/GD/0005 October 2013 First Edition

MEDICAL DEVICE GUIDANCE DOCUMENT

GUIDANCE ON THE PRODUCT GROUPING



Contents

Page

| Prefa | Prefacei | | | |
|------------------------------|---|----------------------------|--|--|
| Intro | duction | iv | | |
| 1 | Purpose | 1 | | |
| 2 | Scope | 1 | | |
| 3 | Term and definitions | 1 | | |
| 4 | General Principles of Grouping | 3 | | |
| 5 | Categories | 5 | | |
| | 5.1 Single | 5 | | |
| | 5.2 System | 5 | | |
| | 5.3 Family | 7 | | |
| | 5.4 Set | 10 | | |
| | 5.5 IVD Test Kit | 11 | | |
| | 5.6 IVD Cluster | 12 | | |
| ANNE ANNE ANNE ANNE | EX 1: Decision Flowchart for Grouping of Products as a System EX 2: Decision Flowchart for Grouping of Medical Devices as a Family EX 3: Permissible Variants in a Family EX 4: Special Grouping Rule for Class A Reusable EX 5: Decision Flowchart for Grouping of Products as a IVD Test Kit EX 6: List of IVD Cluster Categories EX 7: Decision Flowchart for Grouping of Products as An IVD Cluster | 15 16 18 20 21 | | |

| Figure 1: Example of referencing the headquarters as the manufacturer for the purpos | e |
|--|----|
| of grouping | 4 |
| Figure 2: Example on Grouping of Systems as a Family | 9 |
| Figure 3 Example of an IVD CLUSTER | 13 |

Preface

This Guidance Document was prepared by the Medical Device Authority (MDA) to help the industry and healthcare professionals in their quest to comply with the Medical Device Act (Act 737) and the regulations under it.

This Guidance Document shall be read in conjunction with the current laws and regulations used in Malaysia, which include but not limited to the following-

- a) Medical Device Act 2012 (Act 737); and
- b) Medical Device Regulations 2012.

In this Guidance Document, the following verbal forms are used:

- "shall" indicates a requirement;
- "should" indicates a recommendation;
- "may" indicates a permission; and
- "can" indicates a possibility or a capability.

Irrespective of the requirements of this Guidance Document, MDA has the right to request for information or material, or define conditions not specifically described in this document that is deemed necessary for the purpose of regulatory control.

MDA has put much effort to ensure the accuracy and completeness of this guidance document. In the event of any contradiction between the contents of this document and any written law, the latter should take precedence.

MDA reserves the right to amend any part of the guidance document from time to time.

CONTACT INFORMATION For further information, please contact:

MEDICAL DEVICE AUTHORITY

Ministry of Health Malaysia Level 6, Prima 9, Prima Avenue II, Block 3547, Persiaran APEC, 63000 Cyberjaya, Selangor, MALAYSIA Fax: (03) 8230 0200 Email: mdb@mdb.gov.my Website: http://www.mdb.gov.my

Introduction

Under the Medical Device Act 2012, the manufacturer or the Local Authorized Representative of the foreign manufacturer is required to register a medical device before importing, exporting or placing it in the Malaysia market.

There is a wide range of medical devices from a simple medical device to a highly complex and sophisticated medical device. The various components can be sold as a separate component, individual customized pack or group and can be categorized as SINGLE, FAMILY, SYSTEM, SET, IVD TEST KIT, and IVD CLUSTER. Each of the categories mentioned can be submitted in the medical device registration application.

GUIDANCE ON THE PRODUCT GROUPING

1 Purpose

The purpose of this document is to provide guidance to determine the appropriate grouping for medical devices in the medical device registration application.

2 Scope

This document applies to all products that fall within the definition of medical device that has been specified in the Guidance Document: *Definition of Medical Device* (MDA/GD/0006).

3 Terms and definitions

For the purposes of this document, the following terms and definitions apply.

3.1 Accessory

For the purposes of this guidance document, an accessory is an article that is intended specifically by its manufacturer to:

- (a) be used together with a medical device to enable that device to be used in accordance with its intended purpose as a medical device; or
- (b) augment or extend the capabilities of that device in fulfillment of its intended purpose as a medical device;

and therefore should be considered as a medical device.

3.2 Component

One of several possibly unequal subdivisions which together constitute the whole medical device to achieve the latter's intended purpose. A component may be known as a part but not a medical device in its own right.

3.3 Generic Proprietary Name

A unique name given by the manufacturer to identify a medical device as a whole product, also known as the trade name or brand name.

3.4 Intended Purpose

The use for which the medical device is intended according to the specifications of its manufacturer as stated on any or all of the following:

- (a) the label of the medical device;
- (b) the instructions for use of the medical device;
- (c) the promotional materials in relation to the medical device.

3.5 Authorised Representative (AR)

- (a) a person domiciled or resident in Malaysia; or
- (b) a firm or company constituted under the laws of Malaysia,

and carrying on business or practice principally in Malaysia.

3.6 Manufacturer

Means —

- (a) a person who is responsible for
- the design, production, fabrication, assembly, processing, packaging and labelling of a medical device whether or not it is the person, or a subcontractor acting on the person's behalf, who carries out these operations; and
- (ii) assigning to the finished medical device under his own name, its intended purpose and ensuring the finished product meets the regulatory requirement;

Or

- (b) any other person who-
- (i) assembles, packages, processes, fully refurbishes, reprocesses or labels one or more ready- made medical devices; and
- (ii) assigning to the ready- made medical device under his own name, its intended purpose and ensuring the finished product meets the regulatory requirement,

but shall not include the following persons:

(A) Any person who assembles or adapts medical devices in the market that are intended for individual patients; and

(B) Any person who assembles, packages, or adapts medical devices in relation to which the assembling, packaging or adaptation does not change the purpose intended for the medical device.

3.7 Medical Device

Refer to MDA/GD/0006: Definition of Medical Device.

3.8 Reusable Surgical Instrument

Instrument intended for surgical use by cutting, drilling, sawing, scratching, scraping, clamping, retracting, clipping or other surgical procedures, without connection to any active medical device and which are intended by the manufacturer to be reused after appropriate procedures for cleaning, disinfection and/or sterilisation have been carried out.

4 General Principles of Grouping

4.1 Medical devices that can be grouped into one of the following five categories can be submitted in one application for product registration and listing in the Malaysia Medical Device Register (MMDR):

- a) SINGLE;
- b) FAMILY;
- c) SYSTEM;
- d) SET;
- e) IVD TEST KIT;
- f) IVD CLUSTER.

4.2 The Three basic rules must all be fulfilled for the grouping to apply. These are:

- a) one generic proprietary name;
- b) one manufacturer; and
- c) one common intended purpose.

4.3 For the purpose of grouping, the corporate headquarters may be regarded as the manufacturer for its subsidiaries and regional manufacturing sites.




Figure 1: Example of referencing the headquarters as the manufacturer for the purpose of grouping

4.4 For example, TRS MDA ORTHOPAEDIC SYSTEM consists of the following constituent-components (refer to Figure 1):

- a) Instruments from ABC Bhd (a subsidiary of TRS MDA Malaysia),
- b) Instruments from XYZ Bhd (a subsidiary of TRS MDA Mexico),
- c) Plates from TRS MDA Mexico; and
- d) Screws from TRS MDA China

For the purpose of grouping, the manufacturer of TRS ORTHOPAEDIC SYSTEM will be TRS MDA Malaysia (Headquarters).

5 Categories

5.1 Single

A SINGLE medical device is a medical device from a manufacturer identified by a medical device proprietary name with a specific intended purpose. It is sold as a distinct packaged entity. It may be offered in a range of package sizes.

The Examples:

- a) Condoms that are sold in packages of 3, 12 and 144 can be registered as a SINGLE medical device.
- b) A company manufactures a software program that can be used with a number of CT scanners produced by other manufacturers. Although the software cannot function on its own, it can be used on different scanners. The software can be registered as a SINGLE medical device.
- c) A company that assembles and registers a first aid kit has now decided to also supply each of the medical devices in the first aid kit individually. Each medical device supplied individually as a medical device must be registered separately as a SINGLE medical device.

5.2 System

5.2.1 A medical device SYSTEM comprises of a number of constituent-components that are:

- a) from the same manufacturer;
- b) intended to be used in combination to complete a common intended purpose;
- c) compatible when used as a SYSTEM; and
- d) sold under a SYSTEM name or the labelling, instruction for use (IFU), brochures or catalogues for each constituent component states that the constituent component is intended for use with the SYSTEM.

NOTE Constituent-components registered as part of a system shall only be supplied specifically for use with that SYSTEM. Any constituent-component that is meant for supply for use with multiple SYSTEMs should be registered together with each of these other SYSTEMs. Alternatively, these constituent-component(s) that are compatible for use with multiple SYSTEMs must be registered separately.

5.2.2 The decision flowchart for grouping of products as an SYSTEM can be found in Annex 1.

In addition, if several SYSTEMs fulfil the following conditions to be grouped as a FAMILY, they may be registered as a FAMILY:

- a) the SYSTEMs are from the same manufacturer;
- b) the SYSTEMs are of the same risk classification class;
- c) the SYSTEMs have a common intended purpose;
- d) the SYSTEMs have the similar design and manufacturing process; and
- e) key constituent-components of the SYSTEMs have variations that are within the scope of the permissible variants.
- f) has the same generic proprietary name.
- **5.2.3** Individual SYSTEM names may contain additional descriptive phrases.

The Registrant has to undertake the following post-market duties and obligations for all the constituent-components in the registered SYSTEM, regardless of whether the constituent-components are from the same manufacturer of the SYSTEM:

- a) comply with the conditions applicable to the registered medical device and conditions imposed on the Registrant;
- b) submit applications to the Authority for changes made to the registered medical device;
- c) maintain records of supply;
- d) maintain records of complaints;
- e) report defects and adverse effects to the Authority, and
- f) notify the Authority concerning field safety corrective action (FSCA), including recall.

5.2.4 An In Vitro Diagnostic (IVD) Medical Device SYSTEM may typically consist of TEST KITs and instruments (e.g. an analyser designed to be used with that TEST KIT).

Examples:

- a) A hip replacement SYSTEM comprising of femoral and acetabular components can be registered as a SYSTEM. The components must be used in combination to achieve a common intended purpose of total hip replacement. The size of the components may vary.
- b) An electrosurgical unit and its accessories that consist of forceps, electrodes, electrode holders, leads, plug adaptor, when used together for a common intended purpose, can be registered as a SYSTEM.

- c) Optional accessory such as wireless controller is part of In-the-ear hearing aid can be registered as a SYSTEM.
- d) A glucose monitoring SYSTEM comprising of a glucose meter, test strips, control solutions and linearity solutions can be registered as a SYSTEM.

5.3 Family

5.3.1 A medical device FAMILY is a collection of medical devices and each medical device FAMILY member:

- a) is from the same manufacturer;
- b) is of the same risk classification;
- c) has the same medical device proprietary name;
- d) has a common intended purpose;
- e) has the same design and manufacturing process; and
- f) has variations that are within the scope of the permissible variants.

The decision flowchart for grouping of products as an FAMILY can be found in **Annex 2**.

5.3.2 A characteristic of a medical device may be considered a permissible variant if:

- a) the physical design and construction of the medical devices are the same, or very similar;
- b) the manufacturing processes for the medical devices are the same, or very similar;
- c) the intended purpose of the medical devices is the same; and
- d) the risk profile of the medical devices, taking into account the above factors, is the same.

See **Annex 3** for a list of permissible variants in a FAMILY.

5.3.3 If medical devices satisfy the above conditions to be grouped as a FAMILY, but have different device proprietary names, the products will be listed separately on the Malaysia Medical Device Register (MMDR) based on their proprietary name.


5.3.4 Information on all medical devices within a FAMILY must be submitted as part of one product registration application. Only members of a FAMILY that are eventually listed on the register shall be supplied on the market. Those that are not listed shall not be supplied on the market.

5.3.5 The medical device proprietary name must appear on the label of each of the member medical devices. Individual medical device names may contain additional descriptive phrase.

5.3.6 A special grouping rule is applicable for Class A reusable surgical instruments. See **Annex 4** for this grouping rule.

Examples:

- a) Condoms that differ in colour, size and texture but are manufactured from the same material and manufacturing process and share a common intended purpose can be registered as a FAMILY.
- b) IV administrative sets that differ in features such as safety features and length of tubing, but are manufactured from the same material and manufacturing process and share a common intended purpose can be registered as a FAMILY.
- c) Steerable guidewires that are available in various lengths and possess various tip shapes and tip flexibilities can be registered as a FAMILY if their variations fall within the scope of permissible variants.
- d) Spherical contact lens with additional features of UV protection, can be registered as part of a FAMILY, as this feature does not affect the basic design and manufacturing of the lens.
- e) In-the-ear hearing aids which are designed in different sizes to be fitted in the ear (i.e. outer ear, middle ear, and inner ear canal), and have been designed using the same main components including the signal processor and compression circuit, microphone, amplifiers, and receiver, can be registered as a FAMILY.
- f) Automated blood pressure monitors with optional features such as memory storage and print capability can be considered as part of a FAMILY.
- g) Cardiac catheters that are available in a different number of lumens, lengths and diameters can be registered as a FAMILY.
- h) Contact lenses are available as toric lens and spherical lens. These products have different intended purposes and performances. They are designed and manufactured differently. Due to these differences, they shall not be considered as members of a FAMILY.



Note: The key constituent-components, i.e. implantable rods, plates and screws, across the Systems are within permissible variants. For example, differences in lengths of the implantables screws are deemed permissible variants.

Figure 2: Example on Grouping of Systems as a Family

Information on all the constituent-components within a System must be submitted as part of one product registration application. Only constituent- components within a SYSTEM that are eventually on the register shall be supplied on the market. Those that are not listed shall not be supplied on the market

It the constituent-component in a SYSTEM is supplied for use in more than one SYSTEM, such as constituent-components shall be included in the registration application for each of the other SYSTEMs.

5.4 SET

5.4.1 A medical device SET is a collection of two or more medical devices, assembled together as one package by a manufacturer. The medical device SET has the following:

- a) a single proprietary SET name;
- b) a common intended use;
- c) classification allocated to the set is at the level of the highest classified device within the set.

5.4.2 Each medical device in the SET may have different medical device proprietary names and intended purposes, may be designed and manufactured by different manufacturers.

5.4.3 When the SET is registered, the manufacturer is able to customize the set for particular hospitals or physicians, while maintaining the same SET name and intended purpose. When the SET is registered, all other combinations in that SET can be supplied on the market.

5.4.4 The collection of medical devices in a SET may differ in number and combination of products that comprise each SET while maintaining the same proprietary SET name and SET's intended use.

5.4.5 Information on all medical devices within a SET must be submitted as part of one product registration application. Only medical devices within a SET that are eventually listed on the register shall be supplied on the market. Those that are not listed shall not be supplied on the market. Medical devices that are registered as part of a SET must have a SINGLE medical device registration before they are sold separately as individual medical devices.

5.4.6 If a medical device in a SET is supplied for use in another SET, such a medical device shall be included in the registration application of that other SET.

5.4.7 The SET name indicated for the medical device must appear in the product label affixed on the external package of the SET. Individual medical devices in the SET do not require to be labelled with that SET name. Individual medical devices in the SET may contain additional descriptive phrases.

5.4.8 The Registrant has to undertake the following post-market duties and obligations for all the constituent-components in the registered SET, regardless of whether the constituent-components are from the same manufacturer of the SET:

a) comply with the conditions applicable to the registered medical device and conditions imposed on the Registrant;

- b) submit applications to the Authority for changes made to the registered medical device;
- c) maintain records of supply;
- d) maintain records of complaints;
- e) report defects and adverse effects to the Authority and
- f) notify the Authority concerning field safety corrective action (FSCA), including recall.

5.4.9 Examples:

- a) A first aid kit consisting of medical devices such as bandages, gauzes, drapes and thermometers, when assembled together as one package by a manufacturer, can be registered as a SET.
- b) A dressing tray consisting of a number of medical devices when packaged together for convenience to meet a specific purpose by a manufacturer can be can be registered as a SET.
- c) A manufacturer supplies dressing trays customised with different quantity and type of gauze and sutures to different hospitals while maintaining the same SET name and intended purpose.
- d) A promotional pack consisting of different number of medical devices, for example multi-purpose solution, saline solution, and contact lens case, will not require a SET registration. Individual medical devices shall require registration as SINGLE medical devices.

5.5 IVD Test Kit

5.5.1 An IVD TEST KIT is an in vitro diagnostic (IVD) device that consists of reagents or articles that are:

- a) from the same manufacturer;
- b) intended to be used in combination to complete a specific intended purpose;
- c) sold under a single TEST KIT name or the labelling, instructions for use (IFU), brochures or catalogues for each reagents or article states that the component is intended for use with the IVD TEST KIT; and
- d) compatible when used as a TEST KIT.

5.5.2 An IVD TEST KIT does not include the instruments, such as analysers, needed to perform the test.

5.5.3 The decision flowchart for grouping of products as an IVD TEST KIT can be found in **Annex 5**.

5.5.4 Information on all reagents or articles within an IVD TEST KIT must be submitted as part of one product registration application. Only those reagents or articles within an IVD TEST KIT that are eventually listed on the register shall be supplied on the market. Those that are not listed shall not be supplied on the market.

5.5.5 Individual reagents or articles can be supplied separately as replacement items for the kit. If the reagents or articles in a TEST KIT are supplied for use in more than one TEST KIT, such reagents or articles shall be included in the product registration application of each of the other TEST KITS.

5.5.6 Reagents or articles from another manufacturer may be registered with the IVD TEST KIT. The Registrant has to undertake the following post-market duties and obligations for all the reagents and articles in the registered IVD TEST KIT, regardless of whether the reagents or articles are from the same manufacturer of the IVD TEST KIT:

- a) comply with the conditions applicable to the registered medical device and conditions imposed on the Registrant;
- b) submit applications to the Authority for changes made to the registered medical device;
- c) maintain records of supply;
- d) maintain records of complaints;
- e) report defects and adverse effects to the Authority and
- f) notify the Authority concerning field safety corrective action (FSCA), including recall.

5.5.7 Examples:

A Human Immunodeficiency Virus (HIV) Enzyme Linked ImmunoSorbent Assay (ELISA) TEST KIT may contain controls, calibrators and washing buffers. All the reagents and articles are used together to detect HIV and therefore can be registered as a TEST KIT. These reagents and articles can be supplied separately as replacement items for that particular TEST KIT.

5.6 IVD CLUSTER

5.6.1 An IVD CLUSTER comprises of a number of in vitro diagnostic reagents or articles that are:

a) from the same manufacturer;

- b) within risk classification A or B;
- c) of a common test methodology as listed in **Annex 6**; and

d) of the same IVD CLUSTER category as listed in Annex 6.

5.6.2 The IVD CLUSTER may include analysers that are designed for use with the reagents in the IVD CLUSTER.

5.6.3 A closed list of common test methodologies and IVD CLUSTER categories is provided in **Annex 6**.

5.6.4 The decision flowchart for grouping of products as an IVD CLUSTER can be found in **Annex 7**.

5.6.5 Information on all reagents or articles within an IVD CLUSTER must be submitted as part of one product registration application. Only those reagents or articles within an IVD CLUSTER that are eventually listed on the register shall be supplied on the market. Individual reagents or articles that are listed as part of a CLUSTER can be supplied separately.

5.6.6 If a reagent or article is intended for multiple usage categories such that it can be grouped in more than one IVD CLUSTER, the Registrant can choose to group the reagent or article as part of any one of the IVD CLUSTERs it qualifies. Information to support all the intended purposes of the reagent or article must be submitted as part of the product registration application.






Figure 3 Example of an IVD CLUSTER

Individual (single) reagents or articles, test kits or families of reagents or articles within an IVD CLUSTER (Figure 3), shall be listed separately on the Medical Device Register.



ANNEX 1: Decision Flowchart for Grouping of Products as a System



ANNEX 2: Decision Flowchart for Grouping of Medical Devices as a Family

ANNEX 3: Permissible Variants in a Family

| The list of | permissible variants | is a closed and | positive list. |
|-------------|----------------------|-----------------|----------------|
|-------------|----------------------|-----------------|----------------|

| Specific products | Permissible variants | | |
|-----------------------|--|--|--|
| Antibiotic test | (i) Concentrations | | |
| Catheter | (i) Number of lumens in catheter | | |
| | (ii) Material of catheter: PVC (polyvinylchloride), PU | | |
| | (polyurethane), nylon and silicone | | |
| | (iii) Curvature (straight or pigtail) | | |
| | Polymer products-with or without DEPH | | |
| | Stent- delivery system, that is over-the -wire or | | |
| | through the scope | | |
| IV Cannula | (i) Presence of injection port | | |
| | (ii) Presence of safety features | | |
| Condoms | (i) Texture | | |
| | (ii) Flavour | | |
| Contact lens | (i) Diopter, | | |
| | (ii) UV protection | | |
| | (iii) Tinting | | |
| Electrophysiological | (i) Electrode spacing | | |
| Catheter | (ii) (ii) Number of electrodes | | |
| Suture | (i) Number of strands | | |
| | (ii) Pledgets | | |
| Suture passer | (i) Design of jaw, handle or needle | | |
| Dental handpieces | (i) Rotational speed | | |
| | (ii) Material of handpiece | | |
| Dental brackets | (i) Material of bracket | | |
| IVD rapid tests | (i) Different assembly format: cassette, midstream, | | |
| | strip | | |
| IVD urinalysis strips | (i) Different combination of testing configurations | | |
| Polymer Products | (i) With or Without DEHP | | |
| Stent | 1)Delivery system, that is overthe-wire or through | | |
| | the scope | | |
| L | | | |

| Other permissible variants in general |
|--|
| Colour |
| Diameter |
| Flexibility |
| Gauge |
| Holding force |
| Isotope activity level |
| Length |
| Memory storage |
| Print capability |
| Radiopacity |
| Shape |
| Size |
| Volume |
| Width |
| Viscosity (The change in viscosity is solely due to changes in the concentration |
| of constituent material) |
| Type of monitoring (e.g. ceiling mount, wall mount or standing) |
| Dimensional design differences due to pediatric versus adult use (the |
| differences due to the different patient population are permissible, e.g. volume |
| and length) |

ANNEX 4: Special Grouping Rule for Class A Reusable

Surgical Instruments

A special grouping rule is applicable to Class A reusable surgical instruments.

The special grouping rule states that reusable surgical instruments can be grouped together as 1 FAMILY if they satisfy the following conditions:

- are from the same manufacturer
- same overall intended purpose (This refers to the overall intended purpose of the instrument, regardless of location of the body they are used on).

For example, Class A lung retractor and Class A kidney retractor have the same overall intended purpose as they are both retractors. However, lung forceps and lung retractors do not have the same overall intended purpose and therefore cannot be grouped together as a FAMILY.

This special grouping rule is only applicable to Class A reusable surgical instruments. It is not applicable to Class B, C and D reusable surgical instruments.


| Instrument name | Description | Intended purpose |
|--------------------|--------------------------|-----------------------------|
| ABC Dressing | Delicate, Serrated Tips, | To pick up or grasp tissue |
| Forceps | Straight, 4¾" | or items in the surgical |
| | | wound |
| DEF Kidney | Half curved, 222 mm | To grasp renal polyps |
| Forceps | length | |
| HIJ Lung Forceps | Triangular jaws, jaw | To grasp lung tissue |
| | width 11", length 8" | |
| XYZ Uterine Biopsy | Oblong basket jaw, jaw | To grasp tissue during |
| Forceps | size 3x10mm, shaft | transvaginal or transrectal |
| | length 10" | tissue biopsy |

Example:

In the example above, the forceps have the same manufacturer, but have different proprietary names (ABC, DEF, HIJ and XYZ) and different intended purposes. These forceps are Class A medical devices.

These forceps can be grouped as a FAMLY and registered as part of one application on the basis of the special grouping rule for Class A reusable surgical instrument because:

- they are Class A reusable surgical instruments,
- the manufacturer is the same for all instruments, and
- they have the same overall intended purpose (i.e. to grasp).



ANNEX 5: Decision Flowchart for Grouping of Products as a IVD Test Kit

ANNEX 6: List of IVD Cluster Categories

This list of IVD CLUSTER categories is only applicable to **Class A and Class B IVD**. It should be clearly stated in the label or IFU of each reagent or article that it is intended for use, whether alone or in combination, for the same category:

| | Methodology | CLUSTER Category (closed list) | Examples of Analytes |
|---|--------------------|-----------------------------------|---|
| | | | (non-exhaustive list) |
| 1 | Clinical Chemistry | Enzymes | (i) Acid Phosphatase |
| | | | (ii) Alpha-Amylase |
| | | | (iii) Creatine Kinase |
| | | | (iv) Gamma-GlutamylTransferase |
| | | | (v) Lactate Dehydrogenase |
| | | | (vi) Lipase |
| 2 | | Substrates | (i) Albumin |
| | | | (ii) Bilirubin |
| | | | (iii) Urea/Blood Urea Nitrogen |
| | | | (iv) Cholesterol |
| | | | (v) Creatinine |
| | | | (vi) Glucose |
| 3 | | Electrolytes Reagents | (i) Ammonia |
| | | | (ii) Bicarbonate |
| | | | (iii) Calcium |
| | | | (iv) Chloride |
| | | | (v) Magnesium |
| | | | (vi) Phosphate Inorganic/Phosphorus |
| 4 | | Electrolyte Electrodes | (i) Ammonia Electrodes |
| | | | (ii) Carbon Dioxide (Bicarbonate) Electrodes |
| | | | (iii) Calcium Electrodes |
| | | | (iv) Chloride Electrodes |

| | | | (v) Magnesium Electrodes |
|---|-----------------|-----------------------|--|
| | | | (vi) Potassium Electrodes |
| 5 | | Substrate | (i) Creatinine Electrodes |
| | | Electrodes/Biosensors | (ii) Glucose Electrodes |
| | | | (iii) GlycatedHemoglobin Electrodes |
| | | | (iv) Lactate Electrodes |
| | | | (v) Urea Electrodes |
| | | | (vi) Bilirubin Electrodes |
| 6 | Immunochemistry | | (i) Immunoglobulin A |
| | | (without IgE). | (ii) Immunoglobulin D |
| | | | (iii) Immunoglobulin G |
| | | | (iv) Immunoglobulin M |
| | | | (v) Kappa and Lambda chain |
| | | | (vi) Immunofixation kits |
| 7 | | Complement | (i) Complement Component C1q |
| | | Components | (ii) Complement Component C1 inactivator |
| | | | (iii) Complement Component C3/C3c |
| | | | (iv) Complement Component for Bb |
| | | | (v) Complement Component C4 |
| | | | (vi) Complement Component C5a |
| 8 | | Transport Proteins | (i) Albumin |
| | | | (ii) Ceruloplasmin |
| | | | (iii) Haptoglobin |
| | | | (iv) Hemopixin |
| | | | (v) Lactoferrin |
| | | | (vi) Pre-albumin/Transthyretin |
| 9 | | Lipoproteins | (i) Apolipoprotein A I |
| | | | (ii) Apolipoprotein A II |
| | | 1 | |

| | | (iii) Apolipoprotein B |
|----|----------------------------|---|
| | | |
| | | (iv) Apolipoprotein E Sub-typing |
| | | (v) Lipoprotein (a) |
| 10 | Other Specific Proteins | (i) a1-Acid Glycoprotein |
| | FIOLEINS | (ii) a1-Antitrypsin |
| | | (iii) a2-Macroglobulin |
| | | (iv) a1-Microglobulin |
| | | (v) Fibronectin |
| | | (vi) Immuno Reactive Trypsin |
| 11 | Allergy | (i) Immunoglobulin E – Total |
| | | (ii) Immunoglobulin E – Screen |
| | | (iii) Immunoglobulin E – Specific, monotest/monoresult |
| | | (iv) Allergene specific IgA |
| | | (v) Allergene specific IgG |
| 12 | Cancer markers | (i) BR-marker CA15-3 |
| | | (ii) GI-marker CA19-9, CA242 |
| | | (iii) Carcinoembryonic Antigen |
| | | (iv) Total Prostatic Specific Antigen |
| | | (v) Alphafetoprotein (AFP) |
| | | (vi) p53 |
| 13 | Thyroid Function | (i) Free Triiodothyronine |
| | Markers | (ii) Free Thyroxine |
| | | (iii) Thyroid Stimulating Hormone |
| | | (iv) T – Uptake |
| | | (v) Thyroglobulin |
| | | (vi) Neonatal Thyroxine |
| 14 | Fertility/Pregnancy | (i) Androstenedione |
| | Hormones/ Proteins | (ii) Estradiol |

| | | | (iii) Prolactin |
|----|--|--------------------|--|
| | | | (iv) Human Chorionic Gonadotropin Total |
| | | | (v) Human Placental Lactogen |
| | | | (vi) Estriol |
| 15 | | Diabetes Assays | (i) C-Peptide |
| | | (Hormones) | (ii) Glucagon |
| | | | (iii) Insulin |
| | | | (iv)Glycosylated / Glycated Haemoglobin |
| | | | (v) Islet Cell Ab |
| | | | (vi) Proinsulin |
| 16 | | Renal Metabolism | (i) Aldosterone |
| | | Assays | (ii) Angiotensin I / II |
| | | | (iii) Angiotensin Converting Enzyme |
| | | | (iv) Cortisol |
| | | | (v) Renine |
| 17 | | Bone and Mineral | (i) Bone Alkaline Phosphatase |
| | | Metabolism Assays | (ii) Calcitonin |
| | | | (iii) Cross-linked C-Telopeptides |
| | | | (iv) Cross-linkded N-Telopeptides |
| | | | (v) Cyclic Adenosin Monophosphate |
| | | | (vi) Hydroxyproline |
| 18 | | Endocrine Hormones | (i) Adrenocorticotropic Hormone |
| | | and Peptides | (ii) Human Growth Hormone |
| | | | (iii) Insulin-like Growth Factor I |
| | | | (iv) Insulin-like Growth Factor Binding Protein 1 |
| | | | (v) Vasointestinal Peptide |
| | | | (vi) Vasopressin |


| 10 | | | |
|----|---------------------------------|-----------------------------------|--|
| 19 | | Neuroendocrine Function Assays | (i) Bombesin |
| | | | (ii) 17-Hydroxy-Ketosterone |
| | | | (iii) β-Endorphin |
| | | | (iv) Neurotensin |
| | | | (v) Somatostatin |
| | | | (vi) Substance P |
| 20 | | Other Individual and | (i) Gastrin |
| | | Specified Hormones | (ii)Gonadotropin-Releasing Hormone |
| | | | (iii) Melatonine |
| | | | (iv) Pepsinogen |
| | | | (v) Adrenalin |
| | | | (vi) Dopamine |
| 21 | | Anaemia | (i) Erythropoietin |
| | | | (ii) Ferritin |
| | | | (iii) Folate |
| | | | (iv) Iron |
| | | | (v) Iron Binding Capacity |
| | | | (vi) Soluble Transferrin Receptor |
| 22 | | Vitamins | (i) Vitamin B1 |
| | | | (ii) Vitamin B2 |
| | | | (iii) Vitamin B6 |
| | | | (iv) Vitamin B12 |
| | | | (v) Vitamin D (Cholecalciferol) |
| | | | (vi)Intrinsic Factor (Blocking Antibody) |
| 23 | | Non-Immuno | (i) Phenobarbitol |
| | Suppressive Therapeutic Drug | (ii) Digitoxin | |
| | | Monitoring | (iii) Gentamicin |
| | | | (iv) Valproic Acid |
| | | | (v) Caffeine |
| | | | |

| 24 Immunosuppressive Therapeutic Drug Monitoring (i) Cyclosporine (ii) Tacrolimus 25 Toxicology (i) Amphetamines 25 Toxicology (i) Amphetamines 26 Toxicology (i) Amphetamines 26 Auto-immune Diseases (ii) Caceine (iii) Barbiturates 26 Auto-immune Diseases (i) Anti-nuclear antibodies (ANAs) 27 Rheumatoid- Inflammatory Diseases Markers (i) Anti-Streptococcal Hyaluronidase (ii) Anti-Streptococcal Hyaluronidase (iii) Anti-Streptococcal Screening 28 Liver Function (i) MEGX 29 Cardiac Markers (i) BNP/proBNP | | | (vi) Theophylline |
|---|----|-----------------|--|
| 24 Immunosuppressive Therapeutic Drug Monitoring (i) Cyclosporine (ii) Tacrolimus 25 Toxicology (i) Amphetamines 25 Toxicology (i) Amphetamines 26 Toxicology (i) Amphetamines (ii) Barbiturates (iv) Morphines (v) Phencyclidine (vi) Acetaminophen (vii) Catecholamines (viii) Ethanol (ix) Salicylate 26 Auto-immune Diseases (i) Anti-nuclear antibodies (ANAs) (ii) Organ-specific autoantibodies (vi) Circulating Immuno-complex (v) TSH Receptor antibodies (vi) Anti-Streptococcal Hyaluronidase 27 Rheumatoid- Inflammatory Diseases Markers (i) Anti-Streptokinase 28 Liver Function (i) MEGX | | | |
| Therapeutic Monitoring Drug Monitoring (ii) Tacrolimus (iii) Rapamycin (Sirolimus) (iv) Mycophenolate 25 Toxicology (i) Amphetamines (iii) Cocaine (iii) Barbiturates (iii) Barbiturates (iv) Mycophenolate (iv) Morphines (v) Phencyclidine (vi) Acetaminophen (vii) Catecholamines (viii) Ethanol (ix) Salicylate (ii) Anti-nuclear antibodies (ANAs) 26 Auto-immune Diseases (ii) Anti-nuclear antibodies (ANAs) (iii) Organ-specific autoantibodies (vi) Circulating Immuno-complex (vi) TSH Receptor antibodies (vi) Anti-Streptococcal Hyaluronidase [iii] Anti-Streptokinase (iii) Anti-Streptokinase (iii) Anti-Streptokinase (iii) Anti-Streptokinase (iii) Anti-Streptokinase (iii) Anti-Streptococcal Screening 28 Liver Function (i) MEGX | | | |
| Monitoring (ii) Tacrolimus (iii) Rapamycin (Sirolimus) (iv) Mycophenolate 25 Toxicology (i) Amphetamines (ii) Cocaine (iii) Barbiturates (iii) Barbiturates (iv) Morphines (v) Phencyclidine (vi) Acetaminophen (vii) Catecholamines (vii) Catecholamines (viii) Ethanol (ix) Salicylate (i) Anti-nuclear antibodies (ANAs) Diseases (ii) Organ-specific autoantibodies (vi) Organ-specific autoantibodies (vi) TSH Receptor antibodies (vi) Anti-Cardiolipin antibodies (vi) Anti-Streptococcal Hyaluronidase (iii) Anti-Streptokinase (iii) Anti-Streptokinase (iii) Anti-Streptolysin O (vi) Anti-Streptolysin O (vi) Anti-Streptolysin Q (vi) Anti-Streptococcal Screening 28 Liver Function (i) MEGX | 24 | | |
| 25 Toxicology (i) Amphetamines 25 Toxicology (i) Amphetamines (ii) Cocaine (iii) Barbiturates (iv) Morphines (v) Morphines (v) Phencyclidine (vi) Acetaminophen (vii) Catecholamines (viii) Ethanol (ix) Salicylate 26 Auto-immune (i) Anti-nuclear antibodies (ANAs) Diseases (ii) Anti-topoisomerase (iii) Organ-specific autoantibodies (vi) Circulating Immuno-complex (v) TSH Receptor antibodies (vi) Anti-Cardiolipin antibodies (vi) Anti-Streptokinase (iii) Anti-Streptolysin O (iv) C-Reactive Protein (vi) Anti-Streptolysin Q (vi) Anti-Streptolysin Q (vi) Anti-Streptococcal Screening (vi) Anti-Streptococcal Screening 28 Liver Function (i) MEGX | | - | (ii) Tacrolimus |
| 25 Toxicology (i) Amphetamines (ii) Cocaine (iii) Barbiturates (iv) Morphines (v) Phencyclidine (vi) Acetaminophen (vii) Catecholamines (viii) Ethanol (ix) Salicylate (i) Anti-nuclear antibodies (ANAs) 26 Auto-immune (i) Anti-nuclear antibodies (ANAs) Diseases (ii) Anti-topoisomerase (iii) Organ-specific autoantibodies (vi) XFI Receptor antibodies (v) TSH Receptor antibodies (vi) Anti-Cardiolipin antibodies (vi) Anti-Streptococcal Hyaluronidase Inflammatory Diseases Markers (ii) Anti-Streptolysin O (iv) C-Reactive Protein (v) Anti-Streptolysin O (iv) Anti-Streptolysin (vi) Anti-Streptococcal Screening (ii) Anti-Streptococcal Screening (ii) Carbohydrate Deficient Transferrin | | | (iii) Rapamycin (Sirolimus) |
| 26 Grad (ii) Cocaine (iii) Barbiturates (iv) Morphines (v) Phencyclidine (vi) Acetaminophen (vii) Catecholamines (viii) Ethanol (ix) Salicylate 26 Auto-immune Diseases (ii) Anti-nuclear antibodies (ANAs) (iii) Organ-specific autoantibodies (iv) Circulating Immuno-complex (v) TSH Receptor antibodies (vi) Anti-Cardiolipin antibodies (vi) Anti-Streptokinase (iii) Anti-Streptococcal Screening 28 Liver Function (i) MEGX (ii)Carbohydrate Deficient Transferrin | | | (iv) Mycophenolate |
| 26 Auto-immune (ii) Actaminophen 26 Auto-immune (i) Anti-nuclear antibodies (ANAs) 26 Auto-immune (i) Anti-nuclear antibodies (ANAs) 26 (ii) Anti-nuclear antibodies (ANAs) 27 Rheumatoid- Inflammatory (i) Anti-streptococcal Hyaluronidase 27 Rheumatoid- Inflammatory (i) Anti-Streptokinase 28 Liver Function (i) MEGX 28 Liver Function (i) MEGX | 25 | Toxicology | (i) Amphetamines |
| 26 Auto-immune (iv) Morphines 26 Auto-immune (i) Anti-nuclear antibodies (ANAs) Diseases (ii) Anti-topoisomerase (iii) Organ-specific autoantibodies (iv) TSH Receptor antibodies (v) TSH Receptor antibodies 27 Rheumatoid- Inflammatory (i) Anti-Streptococcal Hyaluronidase (ii) Anti-Streptolysin O (iv) C-Reactive Protein (v) Anti-Staphylolysin (v) Anti-Streptococcal Screening 28 Liver Function (i) MEGX | | | (ii) Cocaine |
| 26 Auto-immune (v) Phencyclidine 26 Auto-immune (vi) Catecholamines 26 Auto-immune (i) Anti-nuclear antibodies (ANAs) Diseases (ii) Anti-topoisomerase (iii) Organ-specific autoantibodies (vi) TSH Receptor antibodies (v) TSH Receptor antibodies 27 Rheumatoid-Inflammatory (i) Anti-Streptococcal Hyaluronidase 1nflammatory (ii) Anti-Streptolysin O (iv) C-Reactive Protein (vi) Anti-Streptolysin (vi) Anti-Streptococcal Screening 28 | | | (iii) Barbiturates |
| 26 Auto-immune (vi) Acetaminophen 26 Auto-immune (i) Anti-nuclear antibodies (ANAs) Diseases (ii) Anti-topoisomerase (iii) Organ-specific autoantibodies (vi) Acetaminophen (viii) Carculating Immuno-complex (viii) Circulating Immuno-complex (vi) Anti-Cardiolipin antibodies (vi) Anti-Cardiolipin antibodies 27 Rheumatoid- Inflammatory (i) Anti-Streptococcal Hyaluronidase (iii) Anti-Streptokinase (iii) Anti-Streptolysin O (iv) C-Reactive Protein (v) Anti-Streptococcal Screening (vi) Anti-Streptococcal Screening 28 Liver Function (i) MEGX | | | (iv) Morphines |
| 26 Auto-immune (vii) Catecholamines 26 Auto-immune (i) Anti-nuclear antibodies (ANAs) Diseases (ii) Anti-topoisomerase (iii) Organ-specific autoantibodies (iv) Circulating Immuno-complex (v) TSH Receptor antibodies (v) TSH Receptor antibodies 27 Rheumatoid- Inflammatory (i) Anti-Streptococcal Hyaluronidase 28 Liver Function (i) MEGX 28 Liver Function (i) MEGX | | | (v) Phencyclidine |
| 26 Auto-immune Diseases (i) Anti-nuclear antibodies (ANAs) 26 Auto-immune Diseases (i) Anti-topoisomerase (ii) Organ-specific autoantibodies (ii) Organ-specific autoantibodies (iv) Circulating Immuno-complex (v) TSH Receptor antibodies (v) Anti-Cardiolipin antibodies (v) TSH Receptor antibodies 27 Rheumatoid- Inflammatory Diseases Markers (i) Anti-Streptococcal Hyaluronidase (ii) Anti-Streptolysin O (iv) C-Reactive Protein (v) Anti-Staphylolysin (v) Anti-Streptococcal Screening 28 Liver Function (i) MEGX | | | (vi) Acetaminophen |
| 26 Auto-immune Diseases (i) Anti-nuclear antibodies (ANAs) (ii) Anti-topoisomerase (iii) Organ-specific autoantibodies (iii) Organ-specific autoantibodies (iv) Circulating Immuno-complex (v) TSH Receptor antibodies (v) TSH Receptor antibodies (vi) Anti-Cardiolipin antibodies (vi) Anti-Streptococcal Hyaluronidase Inflammatory (ii) Anti-Streptokinase (iii) Anti-Streptokinase (iii) Anti-Streptokinase (iv) C-Reactive Protein (v) Anti-Staphylolysin (vi) Anti-Streptococcal Screening 28 | | | (vii) Catecholamines |
| 27 Rheumatoid- Inflammatory Diseases Markers (ii) Anti-topoisomerase (iii) Organ-specific autoantibodies (iv) Circulating Immuno-complex (v) TSH Receptor antibodies (vi) Anti-Cardiolipin antibodies 27 Rheumatoid- Inflammatory Diseases Markers (i) Anti-Streptococcal Hyaluronidase (ii) Anti-Streptokinase (iii) Anti-Streptolysin O (iv) C-Reactive Protein (v) Anti-Staphylolysin (vi) Anti-Streptococcal Screening 28 Liver Function (i) MEGX (ii)Carbohydrate Deficient Transferrin | | | (viii) Ethanol (ix) Salicylate |
| 27 Rheumatoid- Inflammatory Diseases Markers (ii) Anti-topoisomerase (iii) Organ-specific autoantibodies (iv) Circulating Immuno-complex (v) TSH Receptor antibodies (vi) Anti-Cardiolipin antibodies 27 Rheumatoid- Inflammatory Diseases Markers (i) Anti-Streptococcal Hyaluronidase (ii) Anti-Streptokinase (iii) Anti-Streptolysin O (iv) C-Reactive Protein (v) Anti-Staphylolysin (vi) Anti-Streptococcal Screening 28 Liver Function (i) MEGX (ii)Carbohydrate Deficient Transferrin | 26 | | (i) Anti-nuclear antibodies (ANAs) |
| 27 Rheumatoid- Inflammatory Diseases Markers (iv) Circulating Immuno-complex (v) TSH Receptor antibodies 27 Rheumatoid- Inflammatory Diseases Markers (i) Anti-Streptococcal Hyaluronidase (iii) Anti-Streptokinase (ii) Anti-Streptokinase (iv) C-Reactive Protein (v) Anti-Staphylolysin (vi) Anti-Streptococcal Screening (vi) Anti-Streptococcal Screening 28 Liver Function (i) MEGX (ii)Carbohydrate Deficient Transferrin (ii)Carbohydrate Deficient Transferrin | | Diseases | (ii) Anti-topoisomerase |
| 27 (v) TSH Receptor antibodies 27 Rheumatoid- Inflammatory Diseases Markers (i) Anti-Streptococcal Hyaluronidase (ii) Anti-Streptokinase (ii) Anti-Streptolysin O (iv) C-Reactive Protein (v) Anti-Streptococcal Screening 28 Liver Function (i) MEGX (ii) Carbohydrate Deficient Transferrin | | | (iii) Organ-specific autoantibodies |
| 27Rheumatoid- Inflammatory Diseases Markers(i) Anti-Cardiolipin antibodies27Rheumatoid- Inflammatory Diseases Markers(i) Anti-Streptococcal Hyaluronidase (ii) Anti-Streptokinase (iii) Anti-Streptolysin O (iv) C-Reactive Protein (v) Anti-Staphylolysin (vi) Anti-Streptococcal Screening28Liver Function(i) MEGX (ii)Carbohydrate Deficient Transferrin | | | (iv) Circulating Immuno-complex |
| 27 Rheumatoid- Inflammatory Diseases Markers (i) Anti-Streptococcal Hyaluronidase (ii) Anti-Streptokinase (ii) Anti-Streptolysin O (iv) C-Reactive Protein (v) Anti-Staphylolysin (v) Anti-Streptococcal Screening 28 Liver Function (i) MEGX (ii) Carbohydrate Deficient Transferrin | | | (v) TSH Receptor antibodies |
| Inflammatory (ii) Anti-Streptokinase Diseases Markers (iii) Anti-Streptolysin O (iv) C-Reactive Protein (v) Anti-Staphylolysin (vi) Anti-Streptococcal Screening (vi) Anti-Streptococcal Screening 28 Liver Function (i) MEGX (ii)Carbohydrate Deficient Transferrin (ii)Carbohydrate Deficient Transferrin | | | (vi) Anti-Cardiolipin antibodies |
| Diseases Markers (ii) Anti-Streptokinase (iii) Anti-Streptolysin O (iv) C-Reactive Protein (v) Anti-Staphylolysin (v) Anti-Streptococcal Screening 28 Liver Function (i) MEGX (ii) Carbohydrate Deficient Transferrin | 27 | | (i) Anti-Streptococcal Hyaluronidase |
| (iv) C-Reactive Protein (v) Anti-Staphylolysin (vi) Anti-Streptococcal Screening 28 Liver Function (i) MEGX (ii)Carbohydrate Deficient Transferrin | | | (ii) Anti-Streptokinase |
| 28 (v) Anti-Staphylolysin 28 Liver Function (i) MEGX (ii)Carbohydrate Deficient Transferrin | | | (iii) Anti-Streptolysin O |
| 28 (vi) Anti-Streptococcal Screening 28 Liver Function (i) MEGX (ii)Carbohydrate Deficient Transferrin | | | (iv) C-Reactive Protein |
| 28 Liver Function (i) MEGX (ii)Carbohydrate Deficient Transferrin | | | (v) Anti-Staphylolysin |
| (ii)Carbohydrate Deficient Transferrin | | | (vi) Anti-Streptococcal Screening |
| | 28 | Liver Function | (i) MEGX |
| 29 Cardiac Markers (i) BNP/proBNP | | | (ii)Carbohydrate Deficient Transferrin |
| | 29 | Cardiac Markers | (i) BNP/proBNP |

| | | | (iii) Croating Kinggo MP |
|----|--|-------------------------------------|---|
| | | | (ii) Creatine Kinase - MB |
| | | | (iii) Myoglobin |
| | | | (iv) Troponin I/T |
| | | | (v) Homocysteine |
| | | | (vi)High-Sensitivity C-Reactive Protein |
| 30 | | Bacterial Infection - Immunology | (i) Bacillus subtilis |
| | | | (ii) Escherichia coli |
| 31 | | Viral Infection – Immunology | (i) Influenza virus |
| 32 | | Parasitic Infection - Immunology | (i) Entamoebahistolytica |
| | | | (ii) Leishmania |
| 33 | | Fungal Infection - Immunology | (i) Candida albicans |
| | | | (ii) Aspergillus |
| 34 | Haematology (Blood tests for transfusions excluded) | Hemoglobin Testing | (i) Hemoglobin determinations (Total Hb) |
| | | | (ii) Fractional oxyhemoglobin (FO2Hb) |
| | | | (iii) Fractional carboxyhemoglobin (FCOHb) |
| | | | (iv) Fractional methemoglobin (FMetHb) |
| | | | (v) Fractional deoxyhemoglobin (FHHb) |
| 35 | | General Coagulation Tests | (i) Prothrombin Time |
| | | | (ii) Thrombin Time |
| | | | (iii) Activated Clotting Time |
| | | | (iv) Activated Partial Thromboplastin Time |
| 36 | | Haemostasis (Coagulation) | (i) Prothrombin |
| | | | (ii) Thrombin |
| | | | (iii) Fibrinogen |
| | | | (iv) Protein C and Protein S reagents |

| · | | | · · · · · · · · · · · · · · · · · · · |
|----|---------------------------------------|---|--|
| | | | (v) C1-inhibitors |
| | | | (vi) Heparin |
| | | | (vii) Alpha-Antiplasmin |
| | | | (viii) Fibrin |
| | | | (ix) Factor XIII |
| | | | (x) Platelet Factor 4 |
| | | | (xi) Plasminogen |
| 37 | | Other Hematology Tests | (i) Complete Blood count |
| | | | (ii) Hematocrit |
| | | | (iii) Erythrocyte Sedimentation rate |
| 38 | | Cytokines (Lymphokines)/ Immunomodulators | (i) Interferons |
| | | | (ii) Soluble Antigens/Receptors |
| | | | (iii) Tumor Necrosis Factors |
| | Histology/Cytology | | (iv) Interleukins |
| | | | (v) Colony Stimulating Factors |
| | | | (vi) Tumor Necrosis Factors Receptors |
| | | | (vii) Interleukins Receptors |
| 39 | | Histology/ Cytology Reagents | (i) Cytochemical Staining |
| | | | (ii) Embedding, Fixing, Mounting media |
| | | | (iii) Stain solutions |
| | | | (iv) Immunohistology kits |
| 40 | Microbiology - culture (i) | Culture Media | (i) Dehydrated culture media (DCM) |
| | Cytochemical | | (ii) Additives for DCM |
| | Staining (ii) Embedding, | | (iii) Prepared Media (Tubes, bottles, |
| | Fixing, Mounting media (iii) Stain | | Plates) |
| | solutions (iv) | | (iv) Cells, Media, Serum for Viral culture |
| 41 | Immunohistology kits | Susceptibility Testing | (i) Erythromycin susceptibility test for |
| | | . , , , | Staphylococcus aureus |
| | | | |

| 42 | | Identification of bacteria by testing for the susceptibility of the bacteria to the certain antibiotics. Biochemical culture Identification (ID) | (ii) Tobramycin susceptibility test for <i>Pseudomonas aeruginosa</i> (iii) Fungal susceptibility testing (i) Gram Negative Manual ID (ii) Gram Positive Manual ID (iii) Other ID Kits Manual - Anaerobes, Fastidious (iv) Mycoplasma |
|----|-------------------|--|--|
| 43 | | Immunological culture Identification (ID) | (i) Streptococci Grouping Slide tests(ii) Serotyping (E.coli, Salmonella, Shigella etc.) |
| 44 | | Nucleic Acid (NA) based culture identification (ID) | (i) NA Identification – MRSA(ii) NA Identification – Other resistance markers |
| 45 | | Serological identification (ID) | (i) For Parasitology and Mycology (Fungi and Yeast) |
| 46 | Molecular Biology | Oncogenes | (i) p53 (ii) MYC (8q24) |
| | | Genes, whose mutation or enhanced expression, turns a normal cell into a cancer cell. | (iii) TERC (3q26) |
| 47 | | Bacterial Infections (Detection by NA Reagents) | (i) Staphylococcal detection(ii) E.coli detection |
| 48 | | Viral Infections (Detection by NA Reagents) | (i) Influenza and Para-influenza NA Reagents |
| 49 | | Fungal Infections | (i) Fungi NA Reagents |



ANNEX 7: Decision Flowchart for Grouping of Products as An IVD Cluster

MEDICAL DEVICE AUTHORITY MINISTRY OF HEALTH, MALAYSIA

Contact Information:

Registration, Licensing and Enforcement Division IVD Registration Unit Medical Device Authority Ministry of Health Malaysia

Level 6, Prima 9, Prima Avenue II, Block 3547, Persiaran APEC, 63000 Cyberjaya, Selangor, MALAYSIA **T**: (03) 8230 0300 **F**: (03) 8230 0200 **Website**: http://www.mdb.gov.my



